Anuncio
Anuncio
XLO
Xilio Therapeutics, Inc. Common Stock
0.70
USDPatrocinado
-0.03
-3.66%
09 ene, 12:47 UTC -5
Apertura
Informes de beneficios de XLO
Ratio de Sorpresa Positivo
XLO superó 10 de las últimas 17 estimaciones.
59%
Próximo informe
Fecha del próximo informe
09 mar 2026
Estimate for Q4 25 (Revenue/ EPS)
$8.04M
/-$0.12
Cambio implícito desde Q3 25 (Revenue/ EPS)
-57.83%
/--
Cambio implícito desde Q4 24 (Revenue/ EPS)
+366.33%
/-40.00%
Xilio Therapeutics, Inc. Common Stock earnings per share and revenue
On 13 nov 2025, XLO reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of -0.03 USD, resulting in a 80.20% surprise. Revenue reached 19.07 millón, compared to an expected 18.82 millón, with a 1.30% difference. The market reacted with a -9.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 2 analistas forecast an EPS of -0.12 USD, with revenue projected to reach 8.04 millón USD, implying an -- of --% EPS, and reducir of -57.83% in Revenue from the last quarter.
Preguntas frecuentes
What were Xilio Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Xilio Therapeutics, Inc. Common Stock reported EPS of $0.00, beating estimates by 80.2%, and revenue of $19.07M, 1.3% above expectations.
How did the market react to Xilio Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -9.28%, changed from $0.77 before the earnings release to $0.70 the day after.
When is Xilio Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 09 mar 2026.
What are the forecasts for Xilio Therapeutics, Inc. Common Stock's next earnings report?
Based on 2
analistas, Xilio Therapeutics, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $8.04M for Q4 2025.
Which companies are reporting earnings today?
Cheque FXEmpire's Earnings Calendar for today's list of reporting companies.
Anuncio